Revenue down by 1 million dollars this quarter when compared to Q2 2021. I'd suspect that Q2 had a better revenue run because of the 11/11 and JD online sales etc, so im not particularly worried. If revnue decreases in Q4, then I will definitely reconsider this investment.
Overall spending has decreased from approx 5.7 million to 3.7 million (Q2 versus Q3) which is a good result for us, further reducing the need for a CR.
Glad to see SOME news on the BeingMate JV and good to see BUB's regaining some control of their business in China with "immaterial" financial impact/demand to the business.
Only negative i can take from the report - no mention of BUBs Vitamins??
Otherwise, see you all again at Q4.
BUB Price at posting:
44.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)